Li Shuzhan, Yang Fan, Ren Xiubao
National Clinical Research Center for Cancer; Key Laboratory of Cancer Immunology and Biotherapy; Key Laboratory of Cancer Prevention and Therapy.
Drug Discov Ther. 2015 Oct;9(5):363-71. doi: 10.5582/ddt.2015.01054.
Hepatocellular carcinoma (HCC) is the most common type of hepatic malignancies, with poor prognosis. Treatment for HCC are limited, especially for patients with advanced disease who are not eligible for curative hepatectomy or hepatic transplantation. Mechanisms of immune response during tumor development have been investigated for decades. The efficacy and safety of immunotherapy have also been tested in clinical treatment of malignancies. Here we reviewed the immunotherapy strategies for HCC, as well as the particularity of liver immune system and the immune tolerance of HCC. Vaccines, adaptive therapy, immune checkpoint blockades and cytokines are included. We hope this review will give us an integral concept on HCC immunotherapy and help the readers to understand the mechanism of immune tolerance in liver cancer.
肝细胞癌（HCC）是最常见的肝脏恶性肿瘤类型，预后较差。HCC的治疗方法有限，尤其是对于那些不符合根治性肝切除术或肝移植条件的晚期疾病患者。几十年来，人们一直在研究肿瘤发生过程中的免疫反应机制。免疫疗法的有效性和安全性也已在恶性肿瘤的临床治疗中得到检验。在此，我们综述了HCC的免疫治疗策略，以及肝脏免疫系统的特殊性和HCC的免疫耐受性。内容包括疫苗、适应性疗法、免疫检查点阻断和细胞因子。我们希望这篇综述能让我们对HCC免疫治疗有一个完整的概念，并帮助读者了解肝癌免疫耐受的机制。
